Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 34,216 | $43.04 | $1,472,656.64 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 22 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,373,087 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 28,599 | $43.05 | $1,231,186.95 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 21 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,303 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 21,624 | $43.50 | $940,644.00 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 20 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,435,902 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 16,537 | $43.49 | $719,194.13 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 19 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,457,526 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 14,739 | $43.06 | $634,661.34 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 18 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,474,063 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 13,275 | $43.53 | $577,860.75 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 17 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,488,802 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 12,971 | $43.48 | $563,979.08 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 16 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,502,077 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 12,787 | $43.45 | $555,595.15 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 15 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,515,048 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 12,623 | $43.47 | $548,721.81 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 14 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,527,835 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 12,457 | $43.51 | $542,004.07 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 13 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,540,458 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 11,908 | $43.42 | $517,045.36 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 12 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,552,915 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 11,804 | $43.07 | $508,398.28 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 11 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,564,823 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 10,725 | $43.52 | $466,752.00 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 10 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,576,627 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 8,427 | $43.37 | $365,478.99 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 9 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,587,352 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 7,584 | $43.36 | $328,842.24 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 8 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,595,779 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 6,960 | $43.44 | $302,342.40 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 7 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,603,363 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 6,284 | $43.54 | $273,605.36 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 6 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,610,323 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 5,812 | $43.24 | $251,310.88 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 5 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,616,607 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 4,489 | $43.34 | $194,553.26 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 4 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,622,419 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 4,392 | $43.43 | $190,744.56 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 3 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,626,908 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 4,258 | $43.40 | $184,797.20 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,631,300 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:03 UTC |
READ IAN CDirector · Executive Chairman
|
SaleCommon Stock | 3,722 | $43.33 | $161,274.26 |
DisclosureSEC source: 0001225208-19-004782 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,635,558 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:54 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 126,366 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-19-004612 · doc4.xml · derivative · entry 14 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 126,366 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:54 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 155,172 | $0.00 Strike: $30.59 | $0.00 |
DisclosureSEC source: 0001225208-19-004612 · doc4.xml · derivative · entry 13 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,172 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:54 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 77,484 | $43.56 | $3,375,203.04 |
DisclosureSEC source: 0001225208-19-004612 · doc4.xml · nonDerivative · entry 6 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,208 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:54 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 14,760 | $43.57 | $643,093.20 |
DisclosureSEC source: 0001225208-19-004612 · doc4.xml · nonDerivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,692 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:54 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 5,927 | $43.58 | $258,298.66 |
DisclosureSEC source: 0001225208-19-004612 · doc4.xml · nonDerivative · entry 4 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,452 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:54 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 2,300 | $43.59 | $100,257.00 |
DisclosureSEC source: 0001225208-19-004612 · doc4.xml · nonDerivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,379 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:54 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 48,582 | $32.23 | $1,565,797.86 |
DisclosureSEC source: 0001225208-19-004612 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price of $42.45)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:54 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 57,609 | $30.59 | $1,762,259.31 |
DisclosureSEC source: 0001225208-19-004612 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price of $42.45)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantStock Appreciation Rights · Derivative | 304,228 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004206 · doc4.xml · derivative · entry 8 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,228 Underlying: Common Stock · 304,228 shares Expires 2026-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantStock Appreciation Rights · Derivative | 361,005 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004206 · doc4.xml · derivative · entry 7 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,005 Underlying: Common Stock · 361,005 shares Expires 2024-02-28 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 15,211 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004207 · doc4.xml · derivative · entry 10 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,211 Underlying: Common Stock · 15,211 shares Expires 2026-02-28 F9 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F9 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 18,050 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004207 · doc4.xml · derivative · entry 9 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,050 Underlying: Common Stock · 18,050 shares Expires 2024-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 3,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004207 · doc4.xml · nonDerivative · entry 6 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,607 F7 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 152,114 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004208 · doc4.xml · derivative · entry 8 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,114 Underlying: Common Stock · 152,114 shares Expires 2026-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 180,503 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004208 · doc4.xml · derivative · entry 7 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,503 Underlying: Common Stock · 180,503 shares Expires 2024-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
Fonseca LidiaExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 41,071 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004209 · doc4.xml · derivative · entry 3 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,071 Underlying: Common Stock · 41,071 shares Expires 2026-02-28 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
Fonseca LidiaExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 48,736 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004209 · doc4.xml · derivative · entry 2 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,736 Underlying: Common Stock · 48,736 shares Expires 2024-02-28 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
Fonseca LidiaExecutive Vice President
|
GrantCommon Stock | 47,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004209 · doc4.xml · nonDerivative · entry 1 Fonseca Lidia · CIK 0001454944 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,510 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 126,762 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004210 · doc4.xml · derivative · entry 6 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,762 Underlying: Common Stock · 126,762 shares Expires 2026-02-28 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:29 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 150,419 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004210 · doc4.xml · derivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,419 Underlying: Common Stock · 150,419 shares Expires 2024-02-28 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
Hwang AngelaGroup President
|
GrantStock Appreciation Rights · Derivative | 101,409 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004212 · doc4.xml · derivative · entry 10 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,409 Underlying: Common Stock · 101,409 shares Expires 2026-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
Hwang AngelaGroup President
|
GrantStock Appreciation Rights · Derivative | 120,335 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004212 · doc4.xml · derivative · entry 9 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,335 Underlying: Common Stock · 120,335 shares Expires 2024-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
GOETTLER MICHAELGroup President
|
GrantStock Appreciation Rights · Derivative | 60,846 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004211 · doc4.xml · derivative · entry 8 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,846 Underlying: Common Stock · 60,846 shares Expires 2026-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
GOETTLER MICHAELGroup President
|
GrantStock Appreciation Rights · Derivative | 72,201 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004211 · doc4.xml · derivative · entry 7 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,201 Underlying: Common Stock · 72,201 shares Expires 2024-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 21,042 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004213 · doc4.xml · derivative · entry 9 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,042 Underlying: Common Stock · 21,042 shares Expires 2026-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 24,970 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004213 · doc4.xml · derivative · entry 8 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,970 Underlying: Common Stock · 24,970 shares Expires 2024-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 76,057 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004214 · doc4.xml · derivative · entry 9 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,057 Underlying: Common Stock · 76,057 shares Expires 2026-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 90,251 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004214 · doc4.xml · derivative · entry 8 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,251 Underlying: Common Stock · 90,251 shares Expires 2024-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.